Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill aims to boost weight loss and fight inflammation

NCT ID NCT07220629

Disease control Sponsor: Rezera (formerly NodThera Limited) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study is testing whether adding an experimental anti-inflammatory drug called NT-0796 to the weight-loss medication semaglutide can help people with obesity lose more weight and reduce inflammation. About 82 adults with a BMI of 30 to 45 will take either the combination or a placebo for 6 months, along with a reduced-calorie diet and exercise. The main goals are to check safety and see if the combination leads to greater weight loss and lower levels of inflammatory markers like hsCRP.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NT-0796 (an oral anti-inflammatory drug) added to semaglutide (a weight-loss medication)
What this could lead to
If it works, this could lead to a more effective combination treatment for obesity, potentially improving weight loss and reducing inflammation.
What could go wrong
This is an early Phase 2a trial with only 82 participants, so results may not be conclusive. The added drug may cause side effects like nausea or vomiting, and it is unclear if it will provide significant benefit over semaglutide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

82 people

The number who actually took part.

Started

Oct 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female aged 18 to 75 years (inclusive) at Screening who have signed informed consent and are willing and able to comply with the study protocol. 2. Have a BMI of ≥30.0 kg/m2 and \<45.0 kg/m2 at Screening. (BMI values should be calculated to one decimal point precision and then assessed in terms of the required range). 3. History of at least one self-reported unsuccessful dietary effort to lose body weight. 4. Meeting requirements for, and intending to start, treatment with sc semaglutide, as per the approved USPI. Exclusion Criteria: 1. Exposure to incretins, irrespective of the indication, within the 12 months prior to Screening. 2. Known hypersensitivity to semaglutide or any of its excipients, or previous inability to tolerate semaglutide. 3. Type 1 or Type 2 Diabetes Mellitus (T1DM or T2DM), and/or HbA1c ≥6.5% (48 mmol/mol) at Screening and/or use of any anti-diabetic medications. 4. History of stroke with residual neurological deficit within 2 years or transient ischemic attack within 6 months prior to Day 1. 5. History of acute coronary syndrome (ACS) including unstable angina, acute myocardial infarction (both ST segment elevation and non-ST segment elevation) within 6 months prior to Day 1.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Investigative Site

    Mesa, Arizona, 85225, United States

  • Investigative Site

    Hialeah, Florida, 33016, United States

  • Investigative Site

    Jacksonville, Florida, 32216, United States

  • Investigative Site

    Miami, Florida, 33147, United States

  • Investigative Site

    Marrero, Louisiana, 70006, United States

  • Investigative Site

    Columbus, Ohio, 43213, United States

  • Investigative Site

    Seabrook, Texas, 77586, United States

  • Investigative Site

    Salt Lake City, Utah, 84124, United States

  • Investigative Site

    Manassas, Virginia, 20110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.